



Stephen H. Schilling, Ph.D.

Partner

+1 919 862 2225 | steve.schilling@alston.com

Raleigh | 555 Fayetteville Street, Suite 600 | Raleigh, NC 27601-3034

Related Services

Intellectual Property ■ Patent Prosecution, Counseling & Review ■ Biotechnology, Chemical & Pharmaceutical ■ Life Sciences

Steve Schilling is a member of Alston & Bird’s Intellectual Property – Patents Group. Steve focuses his practice on all services relating to biotechnology and life sciences patents, including patent application drafting and prosecution, patent counseling and strategic planning, and opinions on patentability, validity, noninfringement, and freedom to operate. Steve has a technical background in cell and molecular biology, genetics, cell signaling, cancer biology, and agricultural biotechnology. He has extensive experience drafting and prosecuting patent applications in technologies including genome editing, CRISPR-Cas, transgenic organisms, immunotherapies, gene therapies, and diagnostics. He manages extensive domestic and international patent portfolios for leading biopharmaceutical companies, biotechnology companies, and universities.

Steve received his A.B. in biophysical chemistry, summa cum laude, from Dartmouth College, where he was awarded the Chandler T. White 1916 Research Prize for his research on photorespiration in Arabidopsis. He received his Ph.D. in pharmacology from Duke University, where he was awarded a National Science Foundation Graduate Research Fellowship and coauthored several book chapters and journal publications. Steve received his J.D., magna cum laude, from the Duke University School of Law. While at Duke Law, he served on the board of directors of the Intellectual Property and Cyberlaw Society and on the editorial board of the *Duke Law Journal*.

Steve has been recognized by *The Best Lawyers in America*® as “One to Watch” in Patent Law 2022–2024.

Representative Experience

- Represented Advaxis Inc., a biopharmaceutical company developing immunotherapies, in a clinical collaboration and licensing deal with Amgen Inc. for a preclinical candidate involving \$65 million in upfront cash and equity investment with \$475 million in development, regulatory and sales milestones and tiered royalties on net sales.
- Developed patent strategies for and managed domestic and international patent portfolios related to genome editing, CRISPR-Cas technology, and transgenic organisms for leading biopharmaceutical company.
- Developed patent strategies for and managed domestic and international patent portfolios related to cancer immunotherapies for clinical stage biotechnology company.
- Developed patent strategies for and managed domestic and international patent portfolios related to transgenic plants for agricultural biotechnology company.
- Developed patent strategies for patent applications related to cancer diagnostic assays for biotechnology company.

Publications & Presentations

Publications

- “PTO Subject Matter Eligibility Guidance: An Ill-Advised Overextension of *Myriad*,” *Biotechnology Law Report*, June 2014.

Professional & Community Engagement

- North Carolina Bar Association
- North Carolina State Bar

Education

- Duke University (J.D., 2012)
- Duke University (Ph.D., 2009)
- Dartmouth College (A.B., 2002)

Admitted to Practice

- North Carolina
- U.S. Patent and Trademark Office